63 results
8-K
EX-99.1
VAPO
Vapotherm Inc
22 Feb 24
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
4:10pm
for respiratory support of patients with chronic or acute breathing disorders. Over 4.2 million patients have been treated with the use of Vapotherm high
8-K
EX-99.1
VAPO
Vapotherm Inc
14 Dec 23
Vapotherm Announces Suspension of NYSE Listing
6:32pm
. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders
8-K
EX-99.1
VAPO
Vapotherm Inc
11 Dec 23
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock
6:45am
-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 4.1 million patients have been treated with the use
8-K
EX-99.1
h874t
8 Nov 23
Vapotherm Reports Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
g9t3 r0aawwy
8 Aug 23
Vapotherm Reports Second Quarter 2023 Financial Results
4:10pm
SD
EX-1.01
v6dg123ceqqt4ssln
24 May 23
Conflict minerals disclosure
4:31pm
424B3
nnwj3r ksye3qw2ax
5 May 23
Prospectus supplement
4:06pm
S-3/A
0wrtp5u 5fgu
3 May 23
Shelf registration (amended)
4:42pm
8-K
EX-99.1
nkxgxcg0w zqn4
3 May 23
Vapotherm Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
qyvci
6 Dec 22
Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price
4:31pm
8-K
EX-99.1
2uuk9h42smwj
22 Nov 22
Vapotherm Announces Amendment to Debt Agreement
6:55am
8-K
EX-99.1
p5d yb8bhvb1zzssiv
2 Nov 22
Vapotherm Reports Third Quarter 2022 Financial Results
4:12pm
8-K
EX-99.1
6ijm9outasxsldrou
3 Oct 22
Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice
4:30pm